GSM gold starGSM Global
中文版 · Chinese

UCB Head-to-Head Phase 3b Trial: Bimzelx Beats Skyrizi on Joint Outcomes in Psoriatic Arthritis

Monday, November 16, 2026 · Health · GSM News

Twenty-four-week results from UCB's BE BOLD Phase 3b head-to-head trial show its biologic bimekizumab (brand name Bimzelx) maintaining a statistically significant advantage over AbbVie's risankizumab (brand name Skyrizi) on a measure of joint disease activity in psoriatic arthritis, the Belgian drugmaker announced at the American College of Rheumatology's annual meeting in Orlando.

Roughly 2.4 million Americans live with psoriatic arthritis. Choosing between two of the most widely prescribed biologics has long meant weighing trial data that never put the drugs in the same study; UCB describes BE BOLD as the first Phase 3b head-to-head superiority trial powered to compare a biologic on a joint-focused endpoint.

On skin clearance, the two drugs were tied at 24 weeks. The separation came on joint symptoms, where bimekizumab held its statistically significant edge. Bimekizumab was approved in 2023 and risankizumab in 2019, and both are widely used across psoriasis and psoriatic arthritis.

Head-to-head trials are considered the most direct form of comparative evidence. The results give clinicians a new reference point for patients whose joint symptoms dominate, though prescribing decisions still weigh skin response, safety, dosing and individual circumstances.

(Source: UCB)

Source: UCB

Published by GSM · USA (original Chinese edition)

Photo: 图片来源:Wikimedia Commons「Swan neck deformity in a 65 year old Rheumatoid Arthritis patient- 2014-05-27 01-49.jpg」(Phoenix119 摄,CC BY-SA 3.0),图中为一名65岁类风湿关节炎患者手部的鹅颈样畸形,关节炎可造成手指关节变形 Image: Wikimedia Commons "Swan neck deformity in a 65 year old Rheumatoid Arthritis patient- 2014-05-27 01-49.jpg" (by Phoenix119, CC BY-SA 3.0), showing the hand of a 65-year-old rheumatoid arthritis patient with swan neck deformity, an example of arthritis-related joint damage

Latest in Health